Related references
Note: Only part of the references are listed.Effect of the Soluble TNF-Antagonist Etanercept on Tumor Necrosis Factor Bioactivity and Stability
Douglas L. Mann et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2008)
The expression of TNF-α converting enzyme at the site of ruptured plaques in patients with acute myocardial infarction
M. Satoh et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2008)
Vascular and fibrinolytic effects of intra-arterial tumor necrosis factor-α in patients with coronary heart disease
SD Robinson et al.
CLINICAL SCIENCE (2006)
Tumor necrosis factor-α as trigger of platelet activation in patients with heart failure
P Pignatelli et al.
BLOOD (2005)
Tumor necrosis factor-α receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction -: The cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study
M Valgimigli et al.
CIRCULATION (2005)
Infliximab improves endothelial dysfunction in systemic vasculitis - A model of vascular inflammation
AD Booth et al.
CIRCULATION (2004)
Targeted anticytokine therapy in patients with chronic heart failure - Results of the Randomized Etanercept Worldwide evALuation (RENEWAL)
DL Mann et al.
CIRCULATION (2004)
Risk of myocardial infarction and stroke after acute infection or vaccination
L Smeeth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis
JP Utz et al.
CHEST (2003)
Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial
ES Chung et al.
CIRCULATION (2003)
Intra-arterial tumor necrosis factor-α impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans
S Chia et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis
D Hürlimann et al.
CIRCULATION (2002)
Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy
FN Witherow et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure
S Fichtlscherer et al.
CIRCULATION (2001)
CD40 signaling and plaque instability
U Schönbeck et al.
CIRCULATION RESEARCH (2001)
Changes in the effects of interleukin-1β and tumor necrosis factor-α on platelet activation in early pregnancy
J Bar et al.
PLATELETS (2001)
Risk factors for cardiovascular disease in systemic lupus erythematosus
E Svenungsson et al.
CIRCULATION (2001)
Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin - Studies in baboons, human coronary intervention, and human acute myocardial infarction
AD Michelson et al.
CIRCULATION (2001)
Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure
B Bozkurt et al.
CIRCULATION (2001)
Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction
PM Ridker et al.
CIRCULATION (2000)
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
PM Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
